49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00189124 (ClinicalTrials.gov) | September 2003 | 13/9/2005 | Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention | Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus? | Systemic Lupus Erythematosus | Drug: Dehydroepiandrosterone (DHEA) | University of Michigan | Arthritis Foundation | Completed | 18 Years | N/A | Female | 13 | Phase 2/Phase 3 | United States |
| 2 | NCT00082511 (ClinicalTrials.gov) | July 2003 | 11/5/2004 | GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids | A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids | Systemic Lupus Erythematosus | Drug: Prasterone (GL701) | Genelabs Technologies | NULL | Completed | 18 Years | N/A | Female | 114 | Phase 3 | United States;Mexico |
| 3 | NCT00053560 (ClinicalTrials.gov) | December 2002 | 30/1/2003 | To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids | A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids | Lupus | Drug: Prasterone (GL701) | Genelabs Technologies | NULL | Active, not recruiting | 18 Years | N/A | Female | 155 | Phase 3 | United States;Mexico |
| 4 | NCT00391924 (ClinicalTrials.gov) | May 2000 | 24/10/2006 | Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome | Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration | Lupus Erythematosus, Systemic;Sjogren's Syndrome | Drug: Dehydroepiandrosterone | UMC Utrecht | University Medical Centre Groningen;Dutch Arthritis Association | Completed | 18 Years | N/A | Female | 120 | Phase 2 | Netherlands |
| 5 | NCT00004662 (ClinicalTrials.gov) | March 1996 | 24/2/2000 | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: dehydroepiandrosterone | National Center for Research Resources (NCRR) | Northwestern University | Completed | 18 Years | N/A | Female | 300 | Phase 3 | NULL | |
| 6 | NCT00004665 (ClinicalTrials.gov) | June 1995 | 24/2/2000 | Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: dehydroepiandrosterone | National Center for Research Resources (NCRR) | Northwestern University | Completed | 18 Years | N/A | Female | 20 | Phase 2 | NULL | |
| 7 | NCT00004795 (ClinicalTrials.gov) | August 1994 | 24/2/2000 | Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: dehydroepiandrosterone | National Center for Research Resources (NCRR) | Northwestern University | Completed | 18 Years | N/A | Female | 190 | Phase 2/Phase 3 | NULL |